TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15625368

Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (HD IL-2)
Number of subjects: 192

Group type: COMPARATOR
Intervention: IL-2 (5 MIU/m2 subcutaneously every 8 hours for three doses on day 1, then daily 5 days/week for 4 weeks) and interferon (5 MIU/m2 subcutaneously three times per week for 4 weeks)
Number of subjects: 192

Group type: COMPARATOR
Intervention: IL-2 and IFN
Number of subjects: 192
Study: 15251318

Group type: EXPERIMENTAL
Intervention: Horse antilymphoblast globulin (ALG) at 10 mg/kg on alternate days (max 6 doses) with low-dose CsA at 8 mg/kg per day and prednisone at 0.25 mg/kg per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: CsA at 15 mg/kg per day and prednisone at 0.5 mg/kg per day
Number of subjects: 100
Study: 10850052

Group type: EXPERIMENTAL
Intervention: Management guidelines for mild and severe pancreatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of pseudocysts
Number of subjects: 0
Study: 8722584

Group type: EXPERIMENTAL
Intervention: Biphasic shock
Number of subjects: 29

Group type: COMPARATOR
Intervention: Monophasic shock
Number of subjects: 29
Study: 1406835

Group type: EXPERIMENTAL
Intervention: Interferon alfa combined with cyclophosphamide, vincristine, prednisone, and doxorubicin (treatment group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine, prednisone, and doxorubicin (control group)
Number of subjects: 0
Study: 3934948

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3312651

Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound
Number of subjects: 900

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Ultrasound with Doppler spectral analysis and oculoplethysmography
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 900
Study: 31159816

Group type: EXPERIMENTAL
Intervention: Augmented reality assistance using Microsoft HoloLens
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (no augmented reality assistance)
Number of subjects: 10
Study: 28178972

Group type: EXPERIMENTAL
Intervention: Socioeconomic, family or school variables
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Perceived parental physical activity level
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Privileged and less privileged socioeconomic status
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Total physical activity score
Number of subjects: 2523
Study: 25185831

Group type: EXPERIMENTAL
Intervention: LSM+yoga
Number of subjects: 184

Group type: COMPARATOR
Intervention: LSM
Number of subjects: 184
Study: 23347693

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 54 mg/day
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 72 mg/day
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: OROS MPH (54 mg and 72 mg)
Number of subjects: 276
Study: 21989464

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 80711

Group type: COMPARATOR
Intervention: Placebo or no statin
Number of subjects: 80711
Study: 18027125

Group type: EXPERIMENTAL
Intervention: Negative age stereotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive age stereotype
Number of subjects: 0
Study: 16551903

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine peribulbar block with general anesthesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: General anesthesia with subcutaneous normal saline injection
Number of subjects: 62
Study: 12135445

Group type: EXPERIMENTAL
Intervention: Corticosteroid iontophoresis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo iontophoresis
Number of subjects: 64
Study: 10447245

Group type: EXPERIMENTAL
Intervention: Iodized salt with an iodine concentration of 25 ppm (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodized oil capsules containing 400 mg iodine (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Market-purchased iodized salt (Group B)
Number of subjects: 0
Study: 7599866

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human tumor necrosis factor-alpha (rhTNF alpha) 60 ng
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study: 2347435

Group type: EXPERIMENTAL
Intervention: 0.75 g/kg ethanol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 15
Study: 117999

Group type: EXPERIMENTAL
Intervention: TRH perfusions (1,200 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRH perfusions
Number of subjects: 0
Study: 28768370

Group type: EXPERIMENTAL
Intervention: Nortriptyline 10 mg once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 27920241

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (monthly group sessions for 3 consecutive months)
Number of subjects: 160
Study: 24820465

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate at 2.4 mg/kg at 0, 12, and 24 hours, then daily
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous quinine at a 20 mg/kg loading dose, then 10 mg/kg three times a day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Quinine infusion
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 94
Study: 23682548

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy, 60 daily sessions at 1.5 atm abs, 100% oxygen, 60 minutes each.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Neuroimaging (subset of participants undergoing neuroimaging: n=17)
Number of subjects: 63
Study: 20228421

Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (50, 100 or 150 mg/day) for two weeks in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quercetin-enriched diets (0.05 to 2 mg/g diet) for 6 weeks in mice
Number of subjects: 0
Study: 18824338

Group type: EXPERIMENTAL
Intervention: Zataria multiflora vaginal cream
Number of subjects: 90

Group type: COMPARATOR
Intervention: metronidazole vaginal gel
Number of subjects: 90
Study: 16390905

Group type: EXPERIMENTAL
Intervention: memantine (5-20 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study: 12584228

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b plus fixed dosing of ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b plus weight based dosing of ribavirin
Number of subjects: 0
Study: 9890315

Group type: EXPERIMENTAL
Intervention: prednisolone, azathioprine, heparin‐warfarin, and dipyridamole for 2 yr (group 1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: heparin‐warfarin and dipyridamole for 2 yr (group 2)
Number of subjects: 78
Study: 8677032

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study: 1835989

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid or recombinant alpha-interferon (2-6 months, ≥2 mega-units thrice weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid or recombinant alpha-interferon (9-18 months, variable dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid or recombinant alpha-interferon
Number of subjects: 0
Study: 6128084

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study: 31914289

Group type: EXPERIMENTAL
Intervention: Modified transseptal suturing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 40
Study: 30657084

Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP) for 11 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP)
Number of subjects: 58
Study: 27371977

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets plus topical repellent (picaridin KBR3023)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Long-lasting insecticidal nets
Number of subjects: 98
Study: 24256459

Group type: EXPERIMENTAL
Intervention: Unstuck and On Target (UOT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Social skills intervention (SS)
Number of subjects: 67
Study: 22855632

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance for continuous sciatic nerve block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nerve stimulation (NS) guidance for continuous sciatic nerve block
Number of subjects: 100
Study: 20688109

Group type: EXPERIMENTAL
Intervention: Inexpensive computer-controlled olfactometer
Number of subjects: 0
Study: 18307459

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) with glargine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 39
Study: 15987919

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 12629071

Group type: EXPERIMENTAL
Intervention: Low-fixed dose, 235 MBq
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High-fixed dose, 350 MBq
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low-adjusted dose, 2.96 MBq (80 micro Ci)/g thyroid adjusted for 24 h radioiodine uptake
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High-adjusted dose, 4.44 MBq (120 micro Ci)/g thyroid adjusted for 24 h radioiodine uptake
Number of subjects: 88

Group type: COMPARATOR
Intervention: Fixed dose methods
Number of subjects: 88

Group type: COMPARATOR
Intervention: Adjusted dose methods
Number of subjects: 88
Study: 10506814

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac sodium eyedrops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 20
Study: 8853810

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuit (Duraflo II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncoated CPB circuit (Univox IC)
Number of subjects: 20
Study: 1535185

Group type: EXPERIMENTAL
Intervention: Desflurane (thiopental adjuvant)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 200
Study: 6228500

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg t.i.d.)
Number of subjects: 16
Study: 31983105

Group type: EXPERIMENTAL
Intervention: Postoperative intensity-modulated radiotherapy (IMRT) with 40-45 Gy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy with IMRT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Concomitant chemotherapy with 3DCRT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy vs Radiotherapy
Number of subjects: 45
Study: 29502804

Group type: EXPERIMENTAL
Intervention: Bolus calculator (n = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard care without a bolus calculator (n = 18)
Number of subjects: 32
Study: 27325467

Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 16
Study: 25453516

Group type: EXPERIMENTAL
Intervention: Boiled Anethum Graveolens seeds
Number of subjects: 153

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 153
Study: 22187629

Group type: EXPERIMENTAL
Intervention: MR imaging findings in patients with acute whiplash injury
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 100
Study: 20447857

Group type: EXPERIMENTAL
Intervention: High-velocity spine manipulation at the L4-L5 level
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (lying in the same position)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-velocity spine manipulation
Number of subjects: 40
Study: 18804276

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 3196

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 3196

Group type: COMPARATOR
Intervention: No erythromycin
Number of subjects: 3196

Group type: COMPARATOR
Intervention: No co-amoxiclav
Number of subjects: 3196
Study: 15982129

Group type: EXPERIMENTAL
Intervention: Integration hypothesis testing with hierarchical stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual-field effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multinomial model
Number of subjects: 0
Study: 12027346

Group type: EXPERIMENTAL
Intervention: Food sharing in dyads (experimental condition)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Actually feeding a morsel of food (experimental condition)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Food sharing in mixed-sex or female dyads (experimental condition)
Number of subjects: 72
Study: 10537435

Group type: EXPERIMENTAL
Intervention: AHA step II diet plus simvastatin (mean dosage 8.11 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AHA step II diet alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart transplantation plus simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No transplantation
Number of subjects: 0
Study: 7703634

Group type: EXPERIMENTAL
Intervention: Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Replenishing Qi and Invigorating Spleen (RQIS)
Number of subjects: 61
Study: 3131389

Group type: EXPERIMENTAL
Intervention: Adjunctive lithium
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29512900

Group type: EXPERIMENTAL
Intervention: Dasatinib at 50 mg/m² and crizotinib at 215 mg/m² once daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dasatinib at 50 mg/m² and crizotinib at 130 mg/m² or 100 mg/m² twice daily
Number of subjects: 25
Study: 26900386

Group type: EXPERIMENTAL
Intervention: L-citrulline 2.4 g/day for 7 days, then 2.4 g 1 hour before cycling trial
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-citrulline 2.4 g/day
Number of subjects: 22
Study: 24299932

Group type: EXPERIMENTAL
Intervention: Prophylactic variable rate phenylephrine infusion starting at 0.75 μg/kg/min (group P)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Infusion of normal saline (group S)
Number of subjects: 80
Study: 22552863

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension program (1 year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension program (6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 20371662

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/d
Number of subjects: 19
Study: 18759067

Group type: EXPERIMENTAL
Intervention: 15 mg/day zinc sulfate for 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.625 mg estrogen + 5 mg medroxyprogesterone acetate/day for 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.625 mg estrogen + 5 mg medroxyprogesterone acetate/day and 15 mg/day zinc sulfate for 2 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no procedure)
Number of subjects: 32
Study: 16463696

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No formal exercise training (Group B)
Number of subjects: 30
Study: 12432700

Group type: EXPERIMENTAL
Intervention: Wide contoured cuff
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard width cylindrical cuff
Number of subjects: 16

Group type: COMPARATOR
Intervention: Doppler method
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Automatic LOP measurement method
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Wide cuff at 200 mmHg
Number of subjects: 16
Study: 10355241

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8777659

Group type: EXPERIMENTAL
Intervention: Nucleotide supplemented group (group N)
Number of subjects: 74
Study: 1950061

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS) for 2 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bed rest for 2 weeks
Number of subjects: 56
Study: 6361553

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 31870049

Group type: EXPERIMENTAL
Intervention: Modified anterolateral approach combined with modified posteromedial approach
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional posterolateral approach combined with medial‐aided
Number of subjects: 108
Study: 27110636

Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treatment-seeking comparison group
Number of subjects: 0
Study: 27964747

Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC) intervention
Number of subjects: 2314

Group type: EXPERIMENTAL
Intervention: Distribution and media campaign of the Woman's Condom (WC)
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Baseline survey (quasi-control arm)
Number of subjects: 2314
Study: 24407920

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 21842174

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Bemiparin)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Low dose aspirin (LDA)
Number of subjects: 141
Study: 19465285

Group type: EXPERIMENTAL
Intervention: Spherical IOL (Sensar AR40e)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Tecnis Z9000)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Both IOLs
Number of subjects: 2
Study: 16875787

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1565
Study: 15247754

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 11787023

Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 10333390

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (normal saline at room temperature infused at 10 mL/min for 60 min, then 3 mL/min until delivery)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (antibiotics and acetaminophen without amnioinfusion)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 7695166

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy started one month before PTCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2262119

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg daily
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg for attacks
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 399
Study: 6892812

Group type: EXPERIMENTAL
Intervention: Epidural morphine injections (2-3 mg in 10 cc saline solution 0.9%)
Number of subjects: 15
Study: 31533691

Group type: EXPERIMENTAL
Intervention: Personalized depression risk information
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 700
Study: 28864688

Group type: EXPERIMENTAL
Intervention: Propofol plus 0.5-0.8 μg/kg fentanyl
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Propofol plus 0.05-0.08 μg/kg sufentanil
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Propofol plus 0.04-0.05 mg/kg dezocine
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Propofol plus 0.04-0.05 mg/kg oxycodone
Number of subjects: 500

Group type: COMPARATOR
Intervention: Propofol (2.4-3 mg/kg) plus 2-2.5 mL saline
Number of subjects: 500
Study: 26475017

Group type: EXPERIMENTAL
Intervention: Community-led total sanitation (CLTS) intervention
Number of subjects: 4532
Study: 25365866

Group type: EXPERIMENTAL
Intervention: Combination of Cycloferon 5% liniment and Polyoxidonium with MetrogilDenta gel
Number of subjects: 98

Group type: COMPARATOR
Intervention: MetrogilDenta gel
Number of subjects: 98
Study: 21988218

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19356868

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise (ME) program
Number of subjects: 77

Group type: COMPARATOR
Intervention: Resistance exercise (RE) program
Number of subjects: 77
Study: 17233817

Group type: EXPERIMENTAL
Intervention: Melphalan plus dexamethasone (M‐Dex)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Melphalan plus prednisone (MP)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Maintenance dexamethasone
Number of subjects: 585

Group type: COMPARATOR
Intervention: Observation (as maintenance therapy)
Number of subjects: 585
Study: 14766686

Group type: EXPERIMENTAL
Intervention: Remifentanil (5 microg.kg(‐1).hr(‐1) infusion, 25 microg boli, refractory period of five minutes)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Propofol (2 mg.kg(‐1).hr(‐1) infusion, 0.5 mg.kg(‐1) boli, refractory period of ten minutes)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 77

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 77
Study: 12370866

Group type: EXPERIMENTAL
Intervention: Ashworth Scale
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Disability Assessment Scale (DAS)
Number of subjects: 9
Study: 9623023

Group type: EXPERIMENTAL
Intervention: Intramuscular ketoprofen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 50
Study: 7814161

Group type: EXPERIMENTAL
Intervention: Atrioventricular synchronous pacing
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Physiological pacing
Number of subjects: 13